AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01705340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT03132558 — intervention group
Intervention type: DRUG
Intervention: Radiopaque Media
Study NCT01276548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol®-PM 260mg/m2 plus Carboplatin 5 AUC
Study NCT01276548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genexol® 175mg/m2 plus Carboplatin 5 AUC
Study NCT02546726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heat & Aerobic Training (HEAT)
Description: Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise steam-room therapy. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
Study NCT02546726 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Only
Description: Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise sitting in the lobby of the fitness facility. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
Study NCT03958318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise plus nutritional suplementation
Description: For 6 months, all participants in the exercise plus nutritional supplementation group will be performing a three-week non-consecutive exercises programme at the facility. All exercises will be undertaken in a large indoor room. The exercise routine will be based on the Otago exercise programme.
Study NCT05250921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticision
Description: Corticision will be performed to enhance teeth alignment.
Study NCT05250921 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fixed appliance
Description: No surgical intervention is going to be applied to the patients in this group.
Study NCT00325507 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TroVax
Description: TroVax 1 x 10E9 TCID 50mL
Study NCT00325507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 250,000 U/kg S/C for cycle 1 and day 1 of subsequent cycles, 125,000U/kg S/C for days 2-5 of cycles 2-6
Study NCT03411018 — intervention group
Intervention type: OTHER
Intervention: Mechanical ventilation exposure
Study NCT00153673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib
Description: Celecoxib 200mg bd
Study NCT00153673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dologesics
Description: Dologesics 2 tablets bd
Study NCT01122446 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo comparator day 1 and 30 in non-diabetic children with multiple islet autoantibodies.~Post diagnosis: Two doses of 20 microgram Diamyd day 1 and 30 in children originally receiving placebo.
Study NCT03958318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: For 6 months, all participants in the exercise group will be performing a three-week non-consecutive exercises programme at the facility. All exercises will be undertaken in a large indoor room. The exercise routine will be based on the Otago exercise programme.
Study NCT01122446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diamyd
Description: 20 microgram day 1 and 30 in non-diabetic children with multiple islet autoantibodies.~Post diagnosis: Two doses of Diamyd followed to children originally receiving Diamyd
Study NCT00794846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg (Clarinex)
Description: Clarinex 5 mg daily x 7 days
Study NCT00794846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine (Zyrtec)
Description: Zyrtec 10 mg daily x 7 days
Study NCT01369199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir and peginterferon
Description: Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon 180 µg sq weekly during weeks 9-48 of treatment.
Study NCT00955474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Quetiapine XR 100 mg/h.s. will be the starting dose and increased by 100 mg q h.s. q day to a target dose of 300 mg/h.s. by day three and continued on 300 mg/h.s. through week three. Between weeks four and eight, there will be flexible dosing up to 800 mg/h.s. or reductions in doses to no lower than 200 mg/h.s. Incremental increases or decreases in dose will be no more than 100 mg/h.s. over a minimum of one week, unless a patient is unable to tolerate the current dose. Patients unable to tolerate at least 200 mg/h.s. will be discontinued from the study.
Study NCT00955474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine XR 100 mg/h.s. will be the starting dose and increased by 100 mg q h.s. q day to a target dose of 300 mg/h.s. by day three and continued on 300 mg/h.s. through week three. Between weeks four and eight, there will be flexible dosing up to 800 mg/h.s. or reductions in doses to no lower than 200 mg/h.s. Incremental increases or decreases in dose will be no more than 100 mg/h.s. over a minimum of one week, unless a patient is unable to tolerate the current dose. Patients unable to tolerate at least 200 mg/h.s. will be discontinued from the study.
Study NCT00955474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: Active comparator arm:~Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m.
Study NCT00955474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Active comparator arm:~Sertraline 50 mg/a.m. starting dose; increased to 100 mg/a.m. at week 2; continued on 100 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 200 mg/a.m. or reductions in doses to no lower than 50 mg/a.m.~Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m.~Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m.
Study NCT01766219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-bis(benzylthio)octanoic acid
Description: Given IV
Study NCT00690417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol (vitamin D3)
Description: low calorie (\~60 calories) cookie-like disc containing 2,500 IU of vitamin D3, taken by mouth daily for 4 months
Study NCT00955474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Active comparator arm:~Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m.
Study NCT01279876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: 3mg oral, daily, one hour before sleep
Study NCT01279876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin
Description: 3mg oral, daily, one hour before sleep
Study NCT04970173 — intervention group
Intervention type: OTHER
Intervention: use of a very low-volume 1L-PEG plus ascorbate (plenvu) or low-volume 2L-PEG plus ascorbate (moviprep) for bowel preparation in open access colonoscopy
Description: Patients are free to choice the kind of BP in an open access booking system colonoscopy. The safety of BPs was assessed by reviewing the clinical and laboratory data of patients who attended the Emergency Department (ED) of the five Hospitals of our Digestive Endoscopy Unit in the 7 days following the colonoscopy. This was feasible since the electronic reporting system is the same across our five Hospitals.
Study NCT01999686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS3233
Study NCT02054130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9929 280 mg
Description: Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
Study NCT00690417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol (vitamin D3)
Description: low calorie (\~60 calories) cookie-like disc containing 2,500 IU of vitamin D3, taken by mouth daily for 4 months
Study NCT03848715 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Endotoxin
Study NCT01551641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chemoradiotherapy
Description: Patients only receive concurrent chemoradiotherapy if their serum VEGF level decrease.
Study NCT01551641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Patients will be given thalidomide combined with concurrent chemoradiotherapy if their serum VEGF level increase or unchanged.
Study NCT01551641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: without thalidomide
Description: Patients only receive concurrent chemoradiotherapy if their serum VEGF level increase or unchanged
Study NCT00784186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone+misoprostol
Description: single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
Study NCT03848715 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01999686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Study NCT01999686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Study NCT01999686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo metformin
Description: Placebo metformin has the same ingredients with Metformin XR caplet, except that it does not contain the active substance (metformin).
Study NCT01999686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo DLBS3233
Description: Placebo DLBS3233 has the same ingredients with DLBS3233 capsule, except that it does not contain the active substance (DLBS3233).
Study NCT02578446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uncemented Triathlon Tritanium CR Total Knee System
Description: Primary Total Knee Replacement
Study NCT02578446 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented Triathlon CR Total Knee System
Description: Primary Total Knee Replacement
Study NCT02778945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg/kg
Description: Neuromuscular block with Rocuronium 0.9 mg/kg for anesthetic induction Infusion of Rocuronium 0.3mg/kg/hr titrated to maintain a post-tetanic count (PTC)0-2 during the operation.
Study NCT02778945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium 0.6 mg/kg
Description: Neuromuscular block with Rocuronium 0.6 mg/kg for anesthetic induction Intermittent bolus i.v injection of Rocuronium 0.15mg/kg for train-of-four (TOF) 1-2 during the operation
Study NCT00640276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pitavastatin
Description: Pitavastatin 2mg daily once
Study NCT00640276 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle Modification
Description: conducting mainly exercises and diet
Study NCT00784186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
Study NCT00784186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo resembling mifepristone taken 24 hours before 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
Study NCT02564419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Activa PC+S
Description: Upon consent, the good candidates will undergo surgical screening that includes a full neurological workup and baseline functional assessment. Subjects that demonstrate feasibility for control will undergo surgery for unilateral implantation of the Activa PC+S as well as the implantation of unilateral subdural strip electrodes (Resume II, model 3587A) over the motor cortex. After 24 hour observation in the hospital, subjects will participate in 24 distinct sessions or visits of testing over a 3-6 month period. During these visits, the sensing, decoding of the implanted device (Activa PC+S) as well as the external stimulation components (Bioness H200) and parameters will be tested and benchmarked. Subjects will participate for 24 sessions and continue to participate in the study until the end of life of the device, at which point the subject may elect to undergo an explant at that time.
Study NCT02856880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test zinc-IPMP toothpaste
Description: Test toothpaste containing 0.6% w/w zinc chloride and 0.1% w/w IPMP and 1426ppm fluoride as sodium fluoride.
Study NCT02856880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test zinc non- IPMP toothpaste
Description: Test toothpaste containing 0.6% w/w zinc chloride, 0% w/w IPMP and 1426ppm fluoride as sodium fluoride.
Study NCT02856880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive control
Description: Positive control toothpaste containing 0.454% w/w stannous fluoride (Fluoride Toothpaste (1100ppm Fluoride as stannous fluoride)).
Study NCT02856880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SLS negative control
Description: Negative control toothpaste containing 2.0% SLS, 0.65% Tegobetain and 1150 ppm fluoride as sodium fluoride
Study NCT02856880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-SLS negative control
Description: Negative control toothpaste containing 1426 ppm fluoride as sodium fluoride
Study NCT00937378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER120
Description: Nasal Spray, once a day
Study NCT00937378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal Spray
Study NCT01281189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: Oral tablet 150mg twice daily for up to 18 months.
Study NCT01281189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet twice daily for up to 18 months.
Study NCT03113513 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fixation of the vaginal apex
Description: In the course of vaginal hysterectomy the vaginal cuff is either fixed to the sacrospinous ligament or to the uterosacral ligament.
Study NCT02671227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal Mg sulfate.
Description: intrathecal Mg sulfate 50 mg.
Study NCT01563107 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Plasma Volume
Description: Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
Study NCT01563107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise Capacity Test - Bicycle
Description: subjects breathe room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
Study NCT01563107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posture Study
Description: Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
Study NCT01320956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre operative nurse consultation and Hypnosis
Description: Pre operative nurse consultation with pain management nurse, the day before surgery and 5 to 10 minutes of hypnosis, just before anesthesia, with trained nurse.
Study NCT01320956 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre operative nurse consultation
Description: Pre operative nurse consultation with pain management nurse. Usual care and anesthesia
Study NCT02204813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of albumin alone (placebo) will be administered for 5.25 hours.
Study NCT02204813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lo-Xenin
Description: A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 4 pmoles/kg/min will be administered for 5.25 hours.
Study NCT02204813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hi-Xenin
Description: A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 12 pmoles/kg/min will be administered for 5.25 hours.
Study NCT02204813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extra Hi-Xenin
Description: A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 24 pmoles/kg/min will be administered for 5.25 hours.
Study NCT03380338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined aerobic and strength exercise
Study NCT02414971 — intervention group
Intervention type: OTHER
Intervention: There is no intervention
Description: There is no intervention
Study NCT01165697 — intervention group
Intervention type: OTHER
Intervention: Fluorescein angiography
Description: Fluorescein angiography once every 6 months for 3 years
Study NCT02197897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: Single-center, two-stage phase-II clinical trial (Simon design)
Study NCT02693327 — intervention group
Intervention type: OTHER
Intervention: Biological Sample
Description: A one time sample will be collected.
Study NCT02693327 — intervention group
Intervention type: OTHER
Intervention: Blood Sample
Description: A one time blood sample will be collected.
Study NCT02467023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muscle stimulation with Niveus medical stimulator
Description: Subjects will be treated five days per week, for 30 minutes each session. Muscle stimulation will be conducted for four seconds every 15 seconds, thus the subjects will undergo four stimulations per minute. Muscle stimulation will be adjusted until there is a visible or palpable bilateral quadriceps contraction.
Study NCT02467023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: measurement of maximal isometric twitch strength
Description: Quadriceps strength will be measured on the initial day of study approximately every seven days thereafter and on the final day of study participation. For this measurement, patients will remain supine in their bed and the dominant leg will be placed on a frame that will hold the knee at a 60° angle. A cuff will be placed around the ankle and connected to an electronic dynamometer that will record the force generated during the stimulation. The muscle will be stimulated to contract with magnetic stimulators placed over the body of the quadriceps muscle and stimulated at 100% of power output.
Study NCT02467023 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: measurement of maximal isometric twitch strength
Description: Quadriceps strength will be measured on the initial day of study approximately every seven days thereafter and on the final day of study participation. For this measurement, patients will remain supine in their bed and the dominant leg will be placed on a frame that will hold the knee at a 60° angle. A cuff will be placed around the ankle and connected to an electronic dynamometer that will record the force generated during the stimulation. The muscle will be stimulated to contract with magnetic stimulators placed over the body of the quadriceps muscle and stimulated at 100% of power output.
Study NCT02467023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle Biopsy
Description: This procedure will be done at the end of participation in the study.The biopsy will be performed with a sterile needle, which will be inserted through the skin. A skin incision (approximately 1/4 long) will be made in order to insert the needle. The biopsy procedure yields two small pieces of muscle tissue (200 mg total), each about half the size of the eraser on a pencil. After the biopsy is taken, the incision will be closed using a steri-strip bandage (no stitches are required), and a sterile dressing will be placed over the site to reduce the risk of bleeding.